Evaluation of the Omnipod DASH in Children and Adolescents With Type 1 Diabetes Mellitus
Study Details
Study Description
Brief Summary
In this study the usability of the Omnipod DASH insulin administration system is evaluated prospectively by two questionnaires. The effect on the metabolic control is evaluated retrospectively by analysis of data from the medical records of the patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
In the study the usability of the Omnipod DASH (= insulin patch pump) is evaluated prospectively by two questionnaires. The first questionnaire concerns practical items on the application of the pump (e.g. Is it easy to fill to pod?), the wearing of the pump (e.g. Is it comfortable to wear the pump?) and the comparison with insulin administration with insulin pens or other insulin pumps (e.g. is it less painful to administrate insulin by the Omnipod DASH pump). The second questionnaire asks for possible problems that the patients experienced during the wearing of the pump (e.g. did you experience an allergic skin reaction). The questions are formulated to be answered by a 5-point likert scale.
The metabolic control is studied retrospectively from data extracted from the medical records, i.e. the results of the determination of HbA1c and the results from continuous glucose monitoring (CGM) at the start, and after 2, 4 and 6 months of the wearing of the Omnipod DASH insulin pump.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Study group Children and adolescents with type 1 diabetes mellitus who started in 2021 in the Jessa Hospital with the Omnipod DASH insulin administration device. |
Behavioral: Questionnaire
Questionnaire about usability of the Omnipod DASH insulin administration system
|
Outcome Measures
Primary Outcome Measures
- Usability of and problems encountered with the Omnipod Dash insulin administration system [Through study completion, an average of 6 months]
Usability of and problems encountered with the Omnipod Dash insulin administration system is evaluated by 2 home made questionnaire evaluated by a 5 point Likert scale. The first questionnaire includes 3 questions about the application of the pod (e.g. it is easy to place the pod), 7 questions about the wearing of the pod (e.g. the pod doesn't hinder me during sleeping) and 11 questions comparing insulin administration with insulin pens (e.g. insulin administration with the pod is more discrete). The second questionnaire includes 9 questions about possible problems with the Omnipod DASH insulin administration system (e.g. I developped an allergic skin reaction).
Secondary Outcome Measures
- Metabolic control of type 1 diabetes mellitus [Before and during the first 6 months of wearing the Omnipod Dash insulin administration system]
Metabolic control of the type 1 diabetes mellitus measured by HbA1c levels and results from continuous glucose measurement data (e.g. time in range, time below range, time above range).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Children and adolescents with type 1 diabetes mellitus
-
Patients who started in 2021 with the Omnipod DASH insulin administration system in the Jessa Hospital
Exclusion Criteria:
-
Children and adolescents without type 1 diabetes mellitus
-
Children and adolescents with type 1 diabetes treated with insulin pens or other insulin pumps
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Jessa Hospital | Hasselt | Limburg | Belgium | B3500 |
Sponsors and Collaborators
- Jessa Hospital
Investigators
- Principal Investigator: Guy Massa, Jessa Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2022/018